Translate
About
Alphamab Oncology (HK:9966) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
Apr 1 2026
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
Mar 26 2026
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
Mar 24 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
Mar 20 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
Recent Videos
Alphamab Oncology 2025 annual report
Mar 27, 2026
Alphamab Oncology (9966) | China’s Innovative drug sector revaluation just beginning | 18-7-2025
Jul 18, 2025
Exciting updates in oncology, brought to you by LucidQuest.
Mar 25, 2025
Exciting updates in oncology, brought to you by LucidQuest.
Mar 25, 2025